Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

Amazon's cloud arm, AWS, has slashed at least hundreds of jobs—including roles in specialist, training, certification, and customer-support teams.

Fortune’s Jason Del Rey breaks down Prime Day’s biggest winners, surprises, and what the sales reveal about Amazon’s ...

Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there.10 stocks we ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working with Novo Nordisk in the future despite the termination of its earlier ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no matter how risky it may be for the company.

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy collaboration turned on the telehealth provider’s selling of a copycat weight-loss ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.